NCT03189641已完成不适用
An Exploratory Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 6
- 主要终点
- In-segment late lumen loss as measured by quantitative coronary angiography (QCA)
研究概览
简要总结
The purpose of the this trial is to evaluate the clinical safety and efficacy of Cilostazol eluting stent system (CES-1) for the treatment of single de novo lesions in native coronary arteries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •<Clinical selection criteria>
- •Patients who have provided written informed consent.
- •Patients who have evidence of myocardial ischemia confirmed by subjective symptoms (chest pain etc.), ST change in the electrocardiogram or objective findings.
- •Patients who are at least 20 years old.
- •<Angiographic selection criteria>
- •Single de novo lesion in native coronary arteries
- •Target vessel diameter is 2.75 mm to 3.25 mm.
- •TIMI flow is 2 or more.
- •Angiographic percent diameter stenosis (by visual estimation) is 75% or more in AHA classification
排除标准
- •<Clinical exclusion criteria>
- •Acute myocardial infarction Patients whose CK-MB or troponin exceeds the facility reference upper limit and have at least one of the following is confirmed are excluded as acute myocardial infarction.
- •Ischemic symptoms and Electrocardiographic findings showing continuous ischemia (eg, ST segment elevation or depression above 1 mm in contiguous leads, or the appearance of a new left bundle branch block).
- •Pathological Q waves on electrocardiogram
- •Myocardial necrotic focus or wall motion abnormality newly confirmed in diagnostic imaging
- •Patients who cannot be given emergency coronary artery bypass grafting (CABG).
- •Patients who cannot be administered antiplatelet drugs. The following cases are conceivable.
- •Significant intracranial hemorrhage, gastrointestinal bleeding, urinary tract hemorrhage etc. within the last 6 months
- •Surgical operation is planned that requires discontinuation of DAPT after the procedure
- •Anticoagulation therapy is underway and the risk of bleeding is high
- •Bleeding tendency due to hemorrhagic diathesis or blood coagulation disorder.
- •Left ventricular ejection fraction (LVEF) is less than 30% within 30 days before the trial registration.
- •Renal dysfunction (Creatinine value exceeds 2.0 mg/dl or in case artificial dialysis).
- •Allergy to cobalt chrome alloy or contrast agent.
- •Patients who are participating in or will planning to participate in other clinical studies that may have clinical implications for the evaluation of this trial.
- •Patients who are pregnant or breast feeding.
- •Patients who are taking Cilostazol.
- •In cases where the Investigator determines that the patient's participation in the trial is inappropriate.
- •<Angiographic exclusion criteria>
- •Lesion in left main coronary trunk
- •Lesion within 5 mm from the ostium right coronary artery
- •Lesion within 5 mm from the ostium left anterior descending/the ostium left circumflex branch
- •Bifurcation lesion
- •Within 1 year after implementing PCI on the target vessel or its branch
- •There are other lesions that require PCI at the time of the procedure
- •Type C of ACC / AHA classification
结局指标
主要结局
In-segment late lumen loss as measured by quantitative coronary angiography (QCA)
时间窗: 9 months
次要结局
- Target Lesion Failure (TLF)(9 Months)
- %Incomplete stent apposition (%ISA) as measured by OCT/OFDI(9 Months)
- Device Success rate(Immediate post-procedure)
- Target Vessel Failure (TVF)(9 Months)
- Stent thrombosis(9 Months)
- Patient Oriented Composite End point (POCE)(9 Months)
- %Volume obstruction as measured by OCT/OFDI(9 Months)
- %Covered strut as measured by OCT/OFDI(9 Months)
- Procedure success rate(At the time of hospital discharge, expected 1or 2 days after of procedure)
- In-stent and in-segment %diameter stenosis (%DS) as measured by QCA(9 Months)
- In-stent and in-segment %Angiographic Binary Restenosis (%ABR)(9 Months)
- Neointima volume as measured by OCT/OFDI(9 Months)
研究者
研究点 (6)
Loading locations...
相似试验
撤回
1 期
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver DiseaseFatty Liver, NonalcoholicNCT04761848Sadat City University120
已完成
4 期
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)Cerebral InfarctionNCT00272454Korea Otsuka Pharmaceutical Co., Ltd.468
已完成
2 期
Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic AnginaVariant AnginaNCT01444885Korea Otsuka Pharmaceutical Co., Ltd.50
已完成
4 期
Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent ImplantationCoronary Artery DiseaseNCT01192724Yonsei University630
Unknown
4 期
Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic EventsType 2 Diabetes MellitusNCT00886574Hanyang University400